Market Research Logo

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018

Summary

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required f


Introduction
Global Markets Direct Report Coverage
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
Atox Bio Ltd
Five Prime Therapeutics Inc
Imugene Ltd
Johnson & Johnson
TheraMAB LLC
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles
ALPN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALPN-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FPT-155 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FR-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reltecimod sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAB-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD28 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones
Featured News & Press Releases
Oct 22, 2018: Alpine Immune Sciences lead program ALPN-101 demonstrates preclinical activity in inflammatory arthritis and neurological inflammation
Oct 04, 2018: Alpine Immune Sciences to Present at Society for Immunotherapy of Cancer 33rd Annual Meeting
Sep 25, 2018: Atox Bio announces Independent Safety Monitoring Committee recommendation to continue Phase 3 study of Reltecimod in necrotizing soft tissue infections
Sep 24, 2018: Alpine Immune Sciences Announces Upcoming Scientific Presentations
Sep 11, 2018: OSE Immunotherapeutics announces issuance of a European Patent protecting FR104, CD28-antagonist immunotherapy
Aug 22, 2018: OSE Immunotherapeutics publishes new efficacy data on FR104, CD28-antagonist immunotherapy
May 29, 2018: Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)
Apr 17, 2018: Alpine Immune Sciences announces preclinical data demonstrating ALPN-202 eliminates tumors and creates persistent tumor resistance in a murine cancer model
Dec 09, 2017: Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease
Dec 06, 2017: Alpine Immune Sciences Announces Preclinical Results Showing Novel Immuno-Oncology Co stimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
Nov 06, 2017: Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
Oct 30, 2017: Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155
Oct 19, 2017: OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy
Oct 18, 2017: Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 25, 2017: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Reltecimod for Necrotizing Soft Tissue Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Atox Bio Ltd, H2 2018
Pipeline by Five Prime Therapeutics Inc, H2 2018
Pipeline by Imugene Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by TheraMAB LLC, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report